Health Care • Hospital/Nursing Management
$270.57 ▲ +2.07
(+0.77%)
MKT CAP: $21.79B • VOL: 1.46M
52W L $158 52W H $283
THC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $21.31B | $20.68B | $20.56B |
| YoY Revenue Growth % | +3.1% | +0.5% | — |
| Gross Profit | $9.38B | $9.10B | $9.05B |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $3.51B | $5.96B | $2.51B |
| Operating Margin % | 16.5% | 28.8% | 12.2% |
| Net Income (GAAP) | $2.37B | $4.06B | $1.31B |
| EBITDA (Normalized) | $4.32B | $6.70B | $3.25B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $3.54B | $2.05B | $2.37B |
| Capital Expenditures (CapEx) | $1.01B | $931.0M | $925.4M |
| Free Cash Flow (FCF) | $2.53B | $1.12B | $1.45B |
| FCF Margin % | 11.9% | 5.4% | 7.0% |
| Return on Invested Capital (ROIC %) | 26.0% | 45.6% | 13.3% |
| Cash & Short-Term Equivalents | $2.88B | $3.02B | $2.71B |
| Total Debt (Short + Long Term) | $9.32B | $9.18B | $5.77B |
| Total Stockholders' Equity | $4.22B | $4.17B | $11.84B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR THC.